News

H. Lundbeck A/S announced that it has signed agreements with Zenobia Therapeutics (Zenobia) and Vernalis plc (Vernalis) which will provide Lundbeck with access to know-how relevant for making inhibitors for Leucine-rich repeat kinases. Lundbeck will...

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced a strategic collaboration with the Institute of Experimental Neurology (INSpe) and the Department of Neurology of the San Raffaele Scientific Institute (Milan, Italy) to advance clinical research projects in...

Allosteric modulation company Addex Pharmaceuticals announced that the company has been awarded EuropaBio’s Most Innovative SME Award. This is the first time that the award has been presented and it attracted applications by 32 companies from 12 countries representing...

Fuxion Biosciences, Inc. announced that the new BioFlux 1000Z system for live cell imaging will be launched at the 50th American Society for Cell Biology Annual Meeting to be held December 11-15, 2010 in Philadelphia, PA. The BioFlux 1000Z...

GlaxoSmithKline plc announced that it has entered into an agreement to acquire Nanjing MeiRui Pharma Co., Ltd (MeiRui) for a cash consideration of approximately $70 million. Ninety per cent of the share capital of MeiRui is to be acquired...

Elan Drug Technologies, a business unit of Elan Corporation, plc announced that Zogenix Inc, its licensee, has completed enrolment in its open-label Phase 3 study (Study 802) of ZX002, a novel, oral, single-entity, controlled-release formulation of hydrocodone. ZX002, which...

Aurobindo Pharma Limited is pleased to announce that the company has received tentative approval from the US FDA to manufacture and market Duloxetine Hydrochloride Delayed-Release Capsules 20mg (base), 30mg (base) and 60mg (base). Duloxetine Hydrochloride Delayed-Release...